髙橋和久 医師 （たかはしかずひさ）

髙橋和久医師は、呼吸器内科一般を専門とし、肺がん、中皮腫だけでなく、アレルギー疾患、感染症、間質性肺炎など幅広い呼吸器系の疾患のスペシャリストである。がんの中で最も死亡率が高く治りにくいとされる肺がん治療にあえて挑みたいと肺がんの治療医師を志したと言う。
また、髙橋医師は、日本で初めて開設した最も古い歴史を有する呼吸器内科専門教室で2005年8月から主任教授として教室の運営にもあたっており、教育や育成、研究に力を入れている。2019年からは順天堂大学医学部附属順天堂医院院長を併任し、病院運営にも関わっている。中国の複数の大学の教授も併任している。
主な研究テーマには、抗がん剤や分子標的薬など、薬剤の耐性機序の解明と克服。薬が効かなくなった患者さんに効く薬を生む「創薬」をめざす。

原則として他の医療機関からの紹介状(診療情報提供書)が必要。紹介状がない場合は、初診時選定療養費として別途費用が必要となる。

1960年　東京都生まれ
1985年　順天堂大学医学部卒業
1994年～1997年　米国ハーバード大学医学部附属マサチューセッツ総合病院 腫瘍外科学留学 ポスドク
2003年　順天堂大学医学部呼吸器内科学講座助教授、順天堂大学大学院医学研究科呼吸器内科学助教授併任
2005年　順天堂大学医学部呼吸器内科学講座教授、順天堂大学大学院医学研究科呼吸器内科学教授併任
2014年　順天堂大学医学部附属順天堂医院　副院長
2019年　順天堂大学医学部附属順天堂医院　院長
2019年　西安交通大学第二附属医院（西北医院）特別栄誉教授
2020年　北京大学客員教授
2021年　中国医科大学客員教授

医学博士、日本呼吸器学会専門医・指導医、日本内科学会 認定内科医・総合内科専門医、日本老年医学会 認定老年病専門医・指導医、日本臨床腫瘍学会暫定指導医

日本内科学会(評議員)
日本呼吸器学会(副理事長、常務理事/理事/代議員/禁煙推進委員会委員長、第63回日本呼吸器学会学術講演会会長（2023年）)
日本肺癌学会(常任理事、理事/評議員/保険委員会委員長/第66回日本肺癌学会学術集会会長（2025年）)
日本癌学会
日本臨床腫瘍学会(評議員)
日本サルコイドーシス/肉芽腫性疾患学会(理事/評議員)
日本呼吸器内視鏡学会(代議員/気管支鏡専門医制度委員会委員)
日本呼吸器内視鏡学会関東部会(幹事)
日本肺癌学会関東部会(幹事)
日本老年医学会(代議員)
日本呼吸ケア・リハビリテーション学会(代議員)
日本免疫学会
日本アレルギー学会

【受賞歴】
2002年　順天堂大学医学部同窓会学術奨励賞
2014年　APSR Harasawa Research Award
2017年　東京都医師会功労賞
2021年　日本医師会優功賞

世界で一番やさしい　肺がん(知ってなおすシリーズ)　高橋和久著　発行/エクスナレッジ
呼吸器内科　診療マニュアル　高橋和久、熱田了編集　日本医学館
講義録　腫瘍学　高橋和久編集　メジカルビュー社
EBMを活かす呼吸器診療　高橋和久、児玉裕三編集　メジカルビュー社
がんサポート　肺がん特集&リハビリテーション2015年9月号　エビデンス社
など多数

【論文】2021年1月-2022年9月までの英文論文のみ
1. Ko R, Shukuya T, Imamura C, Tokito T, Shimada N, Koyama R, Yamada K, Ishii H, Azuma K, Takahashi K. Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations. Transl Lung Cancer Res. 10(1): 183-192, 2021 Jan

2. Miyawaki T, Wakuda K, Kenmotsu H, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ono A, Naito T, Murakami H, Notsu A, Mori K, Harada H, Endo M, Ohde Y, Takahashi K, Takahashi T. Proposing Synchronous Oligometastatic Non-Small Cell Lung Cancer Based on Progression after First-line Systemic Therapy. Cancer Sci. 112(1):359-368, 2021 Jan

3. Kato M, Sasaki S, Tateyama M, Arai Y, Motomura H, Sumiyoshi I, Ochi Y, Watanabe J, Ihara H, Togo S, Takahashi K. Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting. Drug Design, Development and Therapy. 15:223-230, 2021 Jan 18

4. Miyashita Y, Ko R, Shimada N, Mitsuishi Y, Miura K, Matsumoto N, Asao T, Shukuya T, Shibayama R, Koyama R, Takahashi K. Impact of the generation of EGFR-TKIs administered as priortherapy on the effcacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. Thoracic Cancer. 12:329–338, 2021 Feb

5. Wakita M, Idei M, Saito K, Horiuchi Y, Yamatani K, Ishikawa S, Yamamoto T, Igawa G, Hinata M, Kadota K, Kurosawa T, Takahashi S, Saito T, Misawa S, Akazawa C, Naito T, Miida T, Takahashi K, Ai T, Tabe Y. Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests. PLoS One. 16(2):e0246536, 2021 Feb 8

6. Sumiyoshi I, Okabe T, Togo S, Takagi H, Motomura H, Ochi Y, Shimada N, Haraguchi M, Shibayama R, Fujimoto Y, Watanabe J, Iwai M, Kadoya K, Iwakami SI, Takahashi K. High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study. J Transl Med. 19(1):92, 2021 Feb 28

7. Asahina H, Tanaka K, Morita S, Maemondo M, Seike M, Okamoto I, Oizumi S, Kagamu H, Takahashi K, Kikuchi T, Isobe T, Sugio K, Kobayashi K. A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801). Clin Lung Cancer. 22(2):147-151, 2021 Mar

8. Sekimoto Y, Suzuki K, Okura M, Hayashi T, Ebana H, Kumasaka T, Mitani K, Nishino K, Okamoto S, Kobayashi E, Takahashi K, Seyama K. Uncommon radiologic computed tomography appearances of the chest in patients with lymphangioleiomyomatosis. Sci Rep. 11(1):7170, 2021 Mar 30.

9. Hiki M, Tabe Y, Ai T, Matsue Y, Harada N, Sugimoto K, Matsushita Y, Matsushita M, Wakita M, Misawa S, Idei M, Miida T, Tamura N, Takahashi K. Naito T. Seroprevalence of anti-SARS-CoV-2 antibodies in Japanese COVID-19 patients. PLoS One. 16(4): e0249449, 2021 Apr 6

10. Nishino K, Yoshimatsu Y, Muramatsu T, Sekimoto Y, Mitani K, Kobayashi E, Okamoto S, Ebana H, Okada Y, Kurihara M, Suzuki K, Inazawa J, Takahashi K, Watabe T, Seyama K. Isolation and characterisation of lymphatic endothelial cells from lung tissues affected by lymphangioleiomyomatosis. Sci Rep. 11(1):8406, 2021 Apr 16

11. Nakamura IT, Ikegami M, Hasegawa N, Hayashi T, Ueno T, Kawazu M, Yagishita S, Goto Y, i Shinno Y, Kojima Y, Takamochi, Takahashi F, Takahashi K, Mano H, Kohsaka S. Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single-cell level. Cancer Sci. 112(5):2006-2019, 2021 May

12. Iwai M, Tulafu M, Togo S, Kawaji H, Kadoya K, Namba Y, Jin J, Watanabe J, Okabe T, Hidayat M, Sumiyoshi I, Itoh M, Koyama R, Ito Y, Orimo A, Takamochi K, Oh S, Suzuki K, Hayashizaki Y, Yoshida K, Takahashi K. Cancer-associated fibroblast migration in non-small cell lung cancers is modulated by increased integrin α11 expression. Mol Oncol. 15(5): 1507-1527, 2021 May 7.

13. Tajima M, Togo S, Ko R, Koinuma Y, Sumiyoshi I, Torasawa M, Kikuchi N, Shiraishi A, Sasaki S, Kyogoku S, Kuwatsuru R, Takahashi K. CT Guided Needle Biopsy of Peripheral Lesions-Lesion Characteristics That May Increase the Diagnostic Yield and Reduce the Complication Rate. J Clin Med.10(9):2031 2021 May 9

14. Okamoto S, Ebana H, Kurihara M, Mitani K, Kobayashi E, Hayashi T, Sekimoto Y, Nishino K, Otsuji M, Kumasaka T, Takahashi K, Seyama K. Folliculin haploinsufficiency causes cellular dysfunction of pleural mesothelial cells. Sci Rep. 11(1):10814, 2021 May 24

15. Nurwidya F, Takahashi F, Winardi W, Tajima K, Mitsuishi Y, Murakami A, Kobayashi I, Nara T, Hashimoto M, Kato M, Hidayat M, Suina K, Hayakawa D, Asao T, Ko R, Shukuya T, Yae T, Shimada N, Yoshioka Y, Sasaki S, Takahashi K. Zinc-finger E-box-binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib. Thorac Cancer. 12(10):1536-1548, 2021 May

16. Sugiyama A, Shiota S, Yanagihara M, Nakayama H, Tsuiki S, Hayashida K, Inoue Y, Takahashi K. The role of long-term continuous positive airway pressure in the progression of obstructive sleep apnoea: A longitudinal cohort study. J Sleep Res. 16:e13374, 2021 Jun

17. Takeshige T, Harada N, Harada S, Ishimori A, Katsura Y, Sasano H, Sandhu Y, Matsuno K, Makino F, Ito J, Atsuta R, Akiba H, Takahashi K. Chitin induces steroid-resistant airway inflammation and airway hyperresponsiveness in mice. Allergol Int. 70(3):343-350, 2021 Jul

18. Nakamura IT, Kohsaka S, Ikegami M, Ikeuchi H, Ueno T, Li K, Beyett TS, Koyama T, Shimizu T, Yamamoto N, Takahashi F, Takahashi K, Eck MJ, Mano H. Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer. NPJ Precis Oncol. 5(1):66, 2021 Jul 16

19. Ohara K, Kinoshita S, Ando J, Azusawa Y, Ishii M, Harada S, Mitsuishi Y, Asao T, Tajima K, Yamamoto T, Takahashi F, Komatsu N, Takahashi K, Ando M. SCLC-J1, a novel small cell lung cancer cell line. Biochem Biophys Rep. 27:101089, 2021 Jul

20. Matsushita Y, Kusaoi M, Hiki M, Murayama G, Abe Y, Nozawa K, Takahashi K, Yamaji K, Tamura N, Naito T. Combination therapy with plasma exchange and glucocorticoid may be effective for severe COVID-19 infection: A retrospective observational study. Ther Apher Dial. 25(4):390-400, 2021 Aug

21. Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, Narita A, Konuma T, Yamamoto K, Akiyama M, Ishigaki K, Suzuki A, Suzuki K, Obara W, Yamaji K, Takahashi K, Asai S, Takahashi Y, Suzuki T, Shinozaki N, Yamaguchi H, Minami S, Murayama S, Yoshimori K, Nagayama S, Obata D, Higashiyama M, Masumoto A, Koretsune Y; FinnGen, Ito K, Terao C, Yamauchi T, Komuro I, Kadowaki T, Tamiya G, Yamamoto M, Nakamura Y, Kubo M, Murakami Y, Yamamoto K, Kamatani Y, Palotie A, Rivas MA, Daly MJ, Matsuda K, Okada Y. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet. 53(10):1415-1424, 2021 Oct

22. Hasegawa N, Kohsaka S, Kurokawa K, Shinno Y, Takeda Nakamura I, Ueno T, Kojima S, Kawazu M, Suehara Y, Ishijima M, Goto Y, Kojima Y, Yonemori K, Hayashi T, Saito T, Shukuya T, Takahashi F, Takahashi K, Mano H. Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers. Cancer Sci. 112(10):4393-4403, 2021 Oct

23. Miyawaki T, Kenmotsu H, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ko R, Wakuda K, Ono A, Naito T, Murakami H, Mori K, Harada H, Endo M, Takahashi K, Takahashi T. Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study. BMC Cancer. 21(1):1247, 2021 Nov

24. Miyawaki T, Kenmotsu H, Yabe M, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Deguchi S, Mitsuya K, Naito T, Murakami H, Mori K, Harada H, Hayashi N, Takahashi K, Takahashi T. Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis. Invest New Drugs. 39(6):1732-1741, 2021 Dec

25. Saito K, Ai T, Kawai A, Matsui J, Fukushima Y, Kikukawa N, Kyoutou T, Chonan M, Kawakami T, Hosaka Y, Misawa S, Takagi H, Matsushita Y, Hiki M, Okuzawa A, Hori S, Naito T, Miida T, Takahashi K, Tabe Y. Performance and usefulness of a novel automated immunoassay HISCL SARS-CoV-2 Antigen assay kit for the diagnosis of COVID-19. Sci Rep. 11(1):23196, 2021 Dec

26. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature. 600(7889):472-477, 2021 Dec

27. Mimori T, Shukuya T, Ko R, Okuma Y, Koizumi T, Imai H, Takiguchi Y, Miyauchi E, Kagamu H, Sugiyama T, Azuma K, Namba Y, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Kobayashi K, Takahashi K.　Cancers (Basel). Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study11;14(2):331, 2022 Jan

28. Tada H, Mitsudomi T, Misumi T, Sugio K, Tsuboi M, Okamoto I, Iwamoto Y, Sakakura N, Sugawara S, Atagi S, Takahashi T, Hayashi H, Okada M, Inokawa H, Yoshioka H, Takahashi K, Higashiyama M, Yoshino I, Nakagawa K; West Japan Oncology Group. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT). J Clin Oncol. J Clin Oncol. 40(3):231-241, 2022 Jan

29. Wirawan A, Tajima K, Takahashi F, Mitsuishi Y, Winardi W, Hidayat M, Hayakawa D, Matsumoto N, Izumi K, Asao T, Ko R, Shimada N, Takamochi K, Suzuki K, Abe M, Hino O, Sekido Y, Takahashi K. A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma By Suppressing LSD1. Mol Cancer Res. 20(1):127-138, 2022 Jan

30. Jo H, Yoshida T, Horinouchi H, Yagishita S, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Yamamoto N, Takahashi K, Motoi N, Ohe Y. Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab. Cancer Immunol Immunother. 71(2):387-398, 2022 Feb

31. Jo H, Yagishita S, Hayashi Y, Ryu S, Suzuki M, Kohsaka S, Ueno T, Matsumoto Y, Horinouchi H, Ohe Y, Watanabe SI, Motoi N, Yatabe Y, Mano H, Takahashi K, Hamada A. Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non-small Cell Lung Cancer PDX Models with Driver Genetic Alterations. Mol Cancer Ther. 21(2):359-370, 2022 Feb

32. Miyawaki T, Naito T, Yabe M, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Murakami H, Mori K, Harada H, Takahashi K, Takahashi T. Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer. Support Care Cancer. Support Care Cancer. 30(2):1633-1641, 2022 Feb

33. Enomoto K, Eguchi Y, Sato T, Norimoto M, Inoue M, Watanabe A, Sakai T, Yoneyama M, Aoki Y, Orita S, Narita M, Inage K, Shiga Y, Umimura T, Sato M, Suzuki M, Takaoka H, Mizuki N, Kim G, Hozumi T, Hirosawa N, Furuya T, Maki S, Nakamura J, Hagiwara S, Koda M, Akazawa T, Takahashi H, Takahashi K, Ohtori S. Asian Spine J. 16(1):47-55, 2022 Feb

34. Miyawaki E, Kenmotsu H, Shintani Y, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Kiura K, Takahashi K, Yamamoto N, Kawaguchi T, Miyaoka E, Yoshino I, Date H. Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study. BMC Cancer. 22(1):342, 2022 Mar

35. Shimamura SS, Shukuya T, Asao T, Hayakawa D, Kurokawa K, Xu S, Miura K, Mitsuishi Y, Tajima K, Shibayama R, Shimada N, Takahashi F, Takahashi K. Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients? BMC Cancer. 22(1):323, 2022 Mar

36. Ueda S, Ito J, Harada N, Harada S, Sasano H, Sandhu Y, Tanabe Y, Abe S, Shiota S, Kodama Y, Nagaoka T, Makino F, Chiba A, Akiba H, Atsuta R, Miyake S, Takahashi K. Effect of Japanese Cedar Pollen Sublingual Immunotherapy on Asthma Patients with Seasonal Allergic Rhinitis Caused by Japanese Cedar Pollen. Biomolecules. 12(4):518, 2022 Mar

37. Yan Y, Naito T, Tabe Y, Ito K, Nojiri S, Deshpande GA, Seyama K, Takahashi K. Increased delta variant SARS-CoV-2 infections in a highly vaccinated medical center in Japan. Vaccine. 40(23):3103-3108, 2022 May

38. Nitta NA, Sato T, Komura M, Yoshikawa H, Suzuki Y, Mitsui A, Kuwasaki E, Takahashi F, Kodama Y, Seyama K, Takahashi K. Exposure to the heated tobacco product IQOS generates apoptosis-mediated pulmonary emphysema in murine lungs. Am J Physiol Lung Cell Mol Physiol. 322(5):L699-L711, 2022 May

39. Igawa G, Ai T, Yamamoto T, Ito K, Nojiri S, Saito K, Wakita M, Fukuda H, Hori S, Misawa S, Miida T, Seyama K, Takahashi K, Tabe Y, Naito T. Antibody response and seroprevalence in healthcare workers after the BNT162b2 vaccination in a University Hospital at Tokyo. Sci Rep. 12(1):8707, 2022 May

40. Torasawa M, Yoshida T, Yagishita S, Shimoda Y, Shirasawa M, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Takahashi K, Ohe Y. Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis. Lung Cancer. 167:49-57, 2022 May

41. Tsuchiya K, Hosaka Y, Takahashi T, Chonan M, Makita Y, Katayama I, Ai T, Idei M, Horiuchi Y, Yamatani K, Wakita M, Misawa S, Okuzawa A, Miida T, Naito T, Takahashi K, Tabe Y. Clin Lab. 68(6) doi: 10.7754/Clin.Lab.2021.210451, 2022 Jun

42. Nanjo Y, Okuma T, Kuroda Y, Hayakawa E, Shibayama K, Akimoto T, Murashima R, Kanamori K, Tsutsumi T, Suzuki Y, Namba Y, Makino F, Nagashima O, Sasaki S, Takahashi K. Multiple Types of Taste Disorders among Patients with COVID-19. Intern Med. 61(14):2127-2134, 2022 Jul

43. Miyawaki T, Naito T, Doshita K, Kodama H, Mori M, Nishioka N, Iida Y, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ko R, Wakuda K, Ono A, Kenmotsu H, Murakami H, Mori K, Harada H, Endo M, Takahashi K, Takahashi T. Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancer. Thorac Cancer. 13(14):2064-2074, 2022 Jul

44. Miyawaki T, Kenmotsu H, Doshita K, Kodama H, Nishioka N, Iida Y, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ko R, Wakuda K, Ono A, Naito T, Murakami H, Mori K, Harada H, Endo M, Takahashi K, Takahashi T. Clinical impact of tumour burden on the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy in non-small-cell lung cancer. Cancer Med. 2022 Jul 18. doi: 10.1002/cam4.5035. Online ahead of print.

45. Yoshida T, Nagaoka T, Nagata Y, Suzuki Y, Tsutsumi T, Kuriyama S, Watanabe J, Togo S, Takahashi F, Matsushita M, Joki Y, Konishi H, Nunomura S, Izuhara K, Conway SJ, Takahashi K. Periostin-related progression of different types of experimental pulmonary hypertension: A role for M2 macrophage and FGF-2 signalling. Respirology. 27(7):529-538, 2022 Jul

46. Iwamura C, Hirahara K, Kiuchi M, Ikehara S, Azuma K, Shimada T, Kuriyama S, Ohki S, Yamamoto E, Inaba Y, Shiko Y, Aoki A, Kokubo K, Hirasawa R, Hishiya T, Tsuji K, Nagaoka T, Ishikawa S, Kojima A, 20Mito H, Hase R, Kasahara Y, Kuriyama N, Tsukamoto T, Nakamura S, Urushibara T, Kaneda S, Sakao S, Tobiume M, Suzuki Y, Tsujiwaki M, Kubo T, Hasegawa T, Nakase H, Nishida O, Takahashi K, Baba K, Iizumi Y, Okazaki T, Kimura MY, Yoshino I, Igari H, Nakajima H, Suzuki T, Hanaoka H, Nakada TA, Ikehara Y, Yokote K, Nakayama T. Elevated Myl9 reflects the Myl9-containing microthrombi in SARS-CoV-2-induced lung exudative vasculitis and predicts COVID-19 severity. Proc Natl Acad Sci U S A. 119(33):e2203437, 2022 Aug

47. Tanabe Y, Shukuya T, Nagata Y, Watanabe T, Seto K, Takahashi R, Masuda K, Miura K, Tajima K, Hiki M, Hayashi T, Suzuki K, Takahashi K. Successful restart of chemotherapy in a patient with primary mediastinal nonseminomatous germ cell tumor after COVID-19 infection. Thorac Cancer.13(18):2654-2658, 2022 Sep